The first personalized CRISPR gene therapy, successfully administered to patient KJ Muldoon in 2025, has opened a transformative new frontier in treating rare genetic diseases.
H5N1 avian influenza continues spreading through U.S. dairy herds and poultry flocks, raising concerns about mammalian adaptation and food supply disruption.
Novo Nordisk's oral Wegovy pill, the first GLP-1 tablet for weight loss, launched in January 2026 after demonstrating 16.6 percent mean weight loss in clinical…
The continued spread of H5N1 avian influenza through U.S. livestock and declining childhood vaccination rates that threaten America's measles-free status are testing a public health…
Following the world's first personalized CRISPR gene-editing treatment, 2026 is shaping up as a pivotal year for precision medicine, with advances in cancer vaccines, regulatory…
The FDA's approval of oral semaglutide for weight loss marks a new chapter for the blockbuster GLP-1 drug class, with Eli Lilly also racing to…